use
pidotimod
role
immunostimul
discuss
know
sever
decad
nevertheless
still
much
know
understand
mechan
potenti
use
airway
infect
prevent
asthma
non
type
bronchiectasi
adjuv
vaccin
allergen
immunotherapi
still
remain
clearli
unveil
aim
paper
provid
use
updat
review
role
main
avail
immunostimul
give
particular
focu
pidotimod
use
potenti
util
respiratori
diseas
pidotimod
show
use
reduc
need
antibiot
airway
infect
increas
level
immunoglobulin
iga
igm
igg
tlymphocyt
subset
endow
immunomodulatori
activ
affect
innat
adapt
immun
respons
higher
express
hladr
molecul
induct
dendrit
cell
matur
releas
proinflammatori
molecul
stimul
lymphocyt
prolifer
differenti
toward
phenotyp
well
increas
phagocytosi
demonstr
associ
pidotimod
vitro
studi
activ
potenti
use
sever
respiratori
condit
asthma
copd
recurr
respiratori
tract
infect
sinc
earli
hundr
paper
publish
pidotimod
immunostimul
drug
due
action
mechan
potenti
use
children
adult
mostli
prevent
respiratori
tract
infect
asthma
chronic
obstruct
pulmonari
diseas
exacerb
despit
use
antibiot
vaccin
frequenc
respiratori
tract
infect
still
high
infect
disturb
wide
rang
patient
children
elderli
particularli
two
extrem
due
defici
immun
system
immatur
first
case
immunosenesc
second
one
reason
immunostimul
drug
steadili
increas
past
year
get
nowaday
import
visibl
prevent
onset
reduc
durat
airway
infect
immunostimul
heterogen
group
compound
act
nonspecif
immun
system
induc
activ
either
upregul
favor
activ
one
compon
understand
deepli
biolog
function
may
implement
clinic
practic
shape
immun
system
favor
accord
differ
process
want
enhanc
hamper
accord
peculiar
characterist
also
call
biolog
respons
modifi
brm
among
heterogen
group
compound
encompass
synthet
natur
occur
substanc
deserv
brief
discuss
review
articl
briefli
summar
commonli
use
brm
use
treatment
respiratori
diseas
focu
mainli
pidotimod
current
potenti
clinic
use
bacteri
lysat
deriv
blend
bacteri
cultur
antigen
throughout
mechan
chemic
cell
lysi
select
bacteria
includ
streptococcu
pneumonia
streptococcu
pyogen
hemophil
influenza
legionella
pneumophila
moraxella
catarrhali
mycoplasma
pneumonia
chlamydia
pneumonia
streptococcu
aureu
streptococcu
viridan
klebsiella
pneumonia
bacteri
antigen
shown
directli
upregul
innat
adapt
immun
stimul
tolllik
receptor
induc
dendrit
cell
dc
matur
increas
phagocyt
activ
activ
interleukin
receptor
differ
lymphocyt
subset
induc
therefor
cytokin
synthesi
enhanc
product
iga
antibodi
cochran
review
delrionavarro
et
al
conclud
immunostimul
reduc
incid
acut
respiratori
tract
infect
arti
suscept
children
includ
trial
qualiti
gener
poor
high
level
statist
heterogen
howev
subgroup
analysi
bacteri
lysat
studi
show
lower
heterogen
display
slightli
better
qualiti
confirm
subsequ
systemat
review
bv
bacteri
lysat
benefici
effect
bacteri
lysat
children
reduct
usag
antibiot
durat
infecti
episod
faster
improv
symptom
shorter
convalesc
decreas
incid
consequ
infecti
episod
administ
children
subacut
sinus
adult
elderli
polyval
mechan
bacteri
lysat
pmbl
shown
superior
respect
placebo
polyval
chemic
bacteri
lysat
pcml
term
reduc
number
durat
infecti
episod
reduc
need
antibiot
treatment
patient
recurr
respiratori
tract
infect
rrti
moreov
high
pressur
use
pmbl
product
elimin
chemic
contamin
lower
degre
damag
bacteri
antigen
pmbl
also
shown
benefici
chronic
obstruct
pulmonari
diseas
copd
patient
reduc
day
hospit
increas
interv
two
exacerb
reduc
number
day
fever
nonetheless
fail
reduc
number
exacerb
lactoferrin
natur
ironbind
protein
highli
express
epitheli
cell
exocrin
secret
neutrophil
store
molecul
secondari
granul
report
function
alarminlik
molecul
promot
antigen
present
cell
matur
upregul
proinflammatori
cytokin
synthesi
also
potent
antiinflammatori
molecul
monocyt
trigger
tolerogeniclik
program
differenti
dc
report
function
lactoferrin
inhibitori
effect
eosinophil
migrat
interfer
mast
cell
function
effect
immun
balanc
clinic
effect
lactoferrin
supplement
prevent
measur
infecti
diseas
mainli
investig
newborn
preterm
infant
notabl
italian
studi
conduct
manzoni
et
al
show
signific
decreas
incid
sepsi
low
birth
weight
infant
g
receiv
mgd
bovin
lactoferrin
birth
day
life
resveratrol
natur
polyphenol
compound
contain
sever
plant
speci
peanut
grape
berri
shown
resveratrol
effect
wide
rang
biolog
activ
rang
antimicrobi
neuroprotect
antiinflammatori
resveratrol
molecular
interact
still
remain
larg
unknown
howev
shown
act
activ
thought
play
role
activ
modul
treg
balanc
downregul
proinflammatori
cytokin
product
notabl
demonstr
resveratrol
remark
antiinflammatori
effect
copd
patient
antimicrobi
immunomodulatori
effect
studi
vivo
septicaemia
infect
model
system
induc
nontyp
haemophilu
influenza
nthi
show
reduct
nthi
viabil
concomit
reduct
airway
inflamm
furthermor
recent
studi
conduct
wu
et
al
resveratrol
reduc
mortal
lung
injuri
cytokin
level
lung
tissu
aureu
pneumonia
murin
model
base
studi
resveratrol
may
use
acut
phase
pulmonari
infect
monophosphoryl
lipid
mpla
nontox
still
highli
immunogen
deriv
lipid
biolog
activ
part
lipopolysaccharid
lp
endotoxin
tolllik
receptor
agonist
vitro
studi
confirm
mpla
abl
act
parent
molecul
lp
potent
adjuv
increas
function
antigen
present
cell
antibodi
respons
character
product
immunostimul
properti
mpla
use
adjuv
malaria
vaccin
prepar
hepat
b
surfac
antigen
vaccin
papilloma
viru
vaccin
furthermor
shown
mpla
promot
allergeninduc
immun
deviat
favor
respons
confirm
benefici
role
adjuv
allergen
immunotherapi
interestingli
besid
role
adjuv
molecul
demonstr
mpla
administr
induct
system
bacteri
infect
result
improv
surviv
increas
bacteri
clearanc
pidotimod
synthet
dipeptid
molecul
acid
endow
immunomodulatori
activ
affect
innat
adapt
immun
respons
higher
express
toll
like
receptor
tlr
hladr
molecul
induct
dc
matur
releas
proinflammatori
molecul
stimul
lymphocyt
prolifer
differenti
toward
phenotyp
well
increas
phagocytosi
demonstr
associ
pidotimod
vitro
studi
sever
vitro
vivo
studi
human
anim
show
pidotimod
abl
amelior
innat
adapt
immun
enhanc
immun
system
capabl
fight
rrti
especi
children
increas
resist
viral
infect
studi
differ
area
demonstr
benefit
pidotimod
includ
use
hepat
c
hpv
genit
infect
purpura
nephrot
syndrom
immunodepress
individu
children
elderli
consid
good
safeti
profil
one
singl
case
potenti
sever
advers
event
new
onset
purpura
report
associ
intak
pidotimod
common
endpoint
studi
pidotimod
immunomodulatori
activ
abl
improv
clinic
condit
patient
enhanc
stimul
immun
cell
function
act
adapt
innat
immun
clinic
efficaci
pidotimod
decreas
respiratori
tract
infect
paediatr
age
assess
multicent
random
trial
involv
children
age
rang
year
old
regard
fever
durat
need
antibiot
treatment
hospit
school
absenc
recoveri
time
relaps
rate
paramet
significantli
reduc
pidotimodtr
group
clarifi
support
role
pidotimod
treatment
acut
infect
prophylact
role
prevent
rrti
well
known
epitheli
cell
play
primari
defens
role
provid
natur
physic
barrier
also
involv
innat
adapt
immun
respons
mean
sever
mechan
includ
express
tlr
surfac
tlr
pattern
recognit
receptor
molecul
broadli
share
pathogen
molecul
call
pathogenassoci
molecular
pattern
pamp
recognit
pamp
via
tlr
result
activ
nfkb
complex
protein
found
almost
anim
cell
control
dna
transcript
respons
variabl
stimuli
includ
bacteri
viral
infect
activ
nfkb
lead
stimul
innat
immun
cell
releas
differ
cytokin
chemokin
eventu
lead
intern
phagocytosi
attach
pathogen
carta
et
al
design
vitro
studi
evalu
immunomodulatori
effect
pidotimod
demonstr
abl
upregul
express
signific
increas
nfkb
protein
express
nfkb
nuclear
transloc
pidotimod
also
abl
induc
phenotyp
function
matur
mucos
dc
play
import
role
cross
talk
innat
adapt
immun
pidotimod
upregul
express
hladr
costimulatori
surfac
marker
pidotimodinduc
dc
matur
lead
releas
proinflammatori
mediat
lead
increas
recruit
inflammatori
cell
activ
lymphocyt
prolifer
polar
toward
phenotyp
besid
role
epitheli
cell
dc
pidotimod
also
enhanc
cytotox
activ
natur
killer
cell
nk
phagocyt
activ
neutrophil
recent
immunolog
data
conclud
function
disord
cell
could
strictli
relat
develop
rrti
children
zhou
dai
propos
studi
compar
effect
pidotimod
spleen
aminopeptid
cell
immun
enhanc
made
peptid
nucleotid
extract
spleen
healthi
anim
cytokin
balanc
children
rrti
pidotimod
significantli
associ
enhanc
secret
cytokin
mediat
inflammatori
reaction
delay
hypersensit
reaction
spleen
aminopeptid
time
abl
regul
secret
essenti
activ
appropri
mention
pidotimod
effect
decreas
cytokin
increas
cytokin
would
enhanc
immun
system
capabl
fight
infect
also
protect
role
develop
atopi
pidotimod
also
found
regul
express
cell
link
cell
cohort
random
studi
held
children
syndrom
prone
develop
frequent
respiratori
tract
infect
demonstr
pidotimod
significantli
upregul
gene
involv
inflamm
chemotaxi
antimicrobi
activ
moreov
ratio
fluspecif
immunoglobulin
skew
pidotimod
treat
individu
given
associ
season
virosom
adjuv
influenza
vaccin
moreov
increas
product
nasopharyng
salivari
secretori
iga
siga
children
respiratori
tract
infect
treat
pidotimod
demonstr
let
suppos
possibl
direct
effect
pidotimod
b
lymphocyt
anoth
studi
use
nasal
cytolog
evalu
abil
pidotimod
reduc
nasal
inflamm
improv
children
qualiti
life
random
control
studi
involv
children
rrti
nasal
cell
motil
mucociliari
clearanc
presenc
supra
nuclearstria
sn
use
indirect
index
well
nasal
ciliat
cell
improv
seen
cytolog
featur
pidotimod
treat
group
concomit
decreas
frequenc
respiratori
tract
infect
antibiot
consumpt
main
mechan
action
pidotimod
innat
adapt
immun
level
summar
fig
pidotimod
follow
first
order
pharmacokinet
administr
oral
rout
parenter
rout
follow
second
order
pharmacokinet
halflif
h
oral
bioavail
elimin
kidney
without
metabol
plasma
clearanc
l
appar
distribut
volum
l
sever
type
oral
rout
drug
avail
tablet
sachet
vial
bioequival
pidotimod
good
safeti
profil
without
increas
frequenc
report
side
effect
autoimmun
disord
pidotimod
treat
patient
moreov
studi
conduct
mice
show
pidotimod
mutagen
effect
either
howev
singl
report
literatur
purpura
associ
pidotimod
therapi
acut
respiratori
infect
ari
still
pandem
despit
introduct
new
antibiot
vaccin
contribut
reduc
risk
mortal
morbid
remain
widespread
affect
young
elder
peopl
furthermor
socioeconom
burden
ari
remain
high
consid
cost
symptomat
drug
antibiot
hospit
indirect
cost
absenc
work
loss
school
day
common
caus
respiratori
tract
infect
viral
origin
especi
human
rhinovirus
hrv
adenoviru
parainfluenza
viru
respiratori
syncyti
viru
rsv
enteroviru
human
metapneumoviru
coronaviru
addit
influenza
virus
virus
tend
caus
direct
invas
epitheli
cell
respiratori
tract
common
exampl
hrv
use
intercellular
adhes
molecul
icam
gain
access
human
cell
subsequ
stimul
product
proinflammatori
cytokin
includ
chemokin
recruit
monocyt
lead
gener
inflammatori
respons
necrosi
host
infect
cell
decreas
ciliari
clearanc
increas
mucou
secret
event
eventu
caus
subsequ
obstruct
respiratori
tract
impend
drainag
secret
impair
mucociliari
escal
good
media
bacteria
prolifer
secondari
infect
particularli
streptococcu
pneumonia
haemophilu
influenza
staphylococcu
aureu
caus
increas
diseas
sever
mortal
morbid
progress
unfavour
sequela
pneumonia
hand
host
immun
system
tend
control
viral
infect
via
induct
apoptosi
infect
cell
use
differ
mechan
includ
increas
tnfalpha
secret
stimul
natur
killer
nk
cell
secret
perforin
make
pore
infect
cell
result
induct
cellular
apoptosi
stimul
macrophag
neutrophil
produc
reactiv
oxygen
speci
caus
oxid
infect
host
cell
protein
lipid
dna
lead
death
carta
et
al
held
studi
assess
abil
pidotimod
induc
cellular
chang
enhanc
host
immun
system
defend
infect
studi
document
pidotimod
abl
upregul
increas
icam
level
thu
play
protect
role
decreas
suscept
hrv
infect
neutrophilmedi
damag
airway
surfac
anoth
vitro
studi
aim
evalu
effect
pidotimod
immun
system
demonstr
abl
downregul
master
regul
inflammatori
respons
associ
sever
recurr
viral
bronchiol
children
moreov
abl
upregul
protect
molecul
viralinduc
abnorm
inflammatori
respons
lower
respiratori
tract
infect
lrti
acut
bronchiti
pneumonia
repres
common
caus
death
infecti
diseas
fourth
overal
common
caus
death
worldwid
estim
lrti
caus
million
thousand
death
among
million
due
pneumonia
infect
even
incid
lrti
decreas
last
decad
pediatr
popul
lrti
remain
lead
albeit
prevent
caus
death
among
elderli
patient
two
differ
studi
plan
evalu
vivo
immunomodulatori
effect
pidotimod
acut
communityacquir
pneumonia
cap
one
held
children
held
adult
studi
patient
divid
two
group
one
group
receiv
antibiot
antibiot
plu
pidotimod
pidotimod
induc
enforc
immun
system
stimul
protein
lactoferrin
cathepsin
g
myeloperoxidas
known
endow
potent
antibacteri
similarli
import
find
pidotimod
associ
reduc
product
tnfalpha
proinflammatori
cytokin
whose
excess
product
known
neg
prognost
factor
cap
final
find
pidotimod
increas
express
dc
confirm
role
trigger
adapt
immun
respons
studi
indic
pidotimod
significantli
increas
natur
immun
system
respons
infecti
stimulu
via
stimul
dc
matur
increas
secret
pidotimod
found
also
determin
longterm
enhanc
immun
system
activ
upregul
express
gene
involv
inflamm
chemotaxi
besid
gene
antimicrobi
activ
eg
camp
lactoferrin
cathepsin
g
myloperoxidas
thu
reduc
risk
earli
recurr
cap
pilot
project
small
number
patient
immunolog
clinic
primari
endpoint
recent
publish
metaanalysi
assess
total
rct
consist
paediatr
patient
ten
rct
publish
itali
russia
greec
rct
publish
chines
group
nonetheless
appropri
random
method
use
trial
one
studi
explicit
alloc
conceal
sinc
eight
rct
doubleblind
placebo
control
evid
assess
high
qualiti
metaanalysi
indic
treatment
pidotimod
result
signific
increas
proport
particip
lower
respiratori
tract
infect
rr
ci
p
compar
convent
treatment
pidotimod
could
significantli
decreas
durat
cough
fever
number
patient
use
antibiot
also
remark
decreas
pidotimod
treatment
group
moreov
pidotimod
administr
improv
level
serum
immunoglobulin
igg
iga
igm
tlymphocyt
subtyp
besid
pidotimod
administr
increas
risk
advers
event
caus
rr
ci
p
copd
chronic
inflammatori
airway
diseas
character
chronic
fix
airway
obstruct
affect
popul
associ
high
morbid
mortal
thirdrank
caus
death
unit
state
caus
deceas
annual
one
main
caus
morbid
clinician
offic
visit
hospit
admiss
loss
work
day
industri
countri
copd
result
complex
interact
environment
mainli
tobacco
smoke
andor
pollut
molecular
risk
factor
molecular
risk
factor
copd
includ
plethora
gene
polymorph
dysregul
antioxid
pool
metalloproteinas
abnorm
uncontrol
role
elastas
copd
exacerb
trigger
often
respiratori
viral
infect
mainli
rhinovirus
even
bacteri
compon
present
moreov
exacerb
tend
sever
prolong
caus
viral
pathogen
term
immunolog
respons
asid
inflamm
usual
neutrophil
recruit
sputum
eosinophilia
also
relev
particular
viral
infect
reduct
exacerb
frequenc
intens
paramount
diseas
control
appear
fundament
act
immun
system
order
prevent
infect
reach
optimum
care
due
role
potenti
regul
innat
acquir
immun
system
pidotimod
appear
promis
also
copd
two
italian
doubleblind
random
trial
pidotimod
show
signific
reduct
infect
copd
exacerb
pidotimod
treat
patient
posit
effect
present
treatment
period
also
follow
suggest
protect
action
drug
possibl
use
cyclic
regimen
longlast
effect
pidotimod
furtherli
confirm
demonstr
potenti
immun
respons
week
infect
pidotimod
found
effect
also
particularli
suscept
popul
elderli
copd
patient
popul
patient
sever
copd
differ
degre
immunolog
sign
immunosenesc
achiev
reduc
number
exacerb
concomit
use
pidotimod
flu
vaccin
compar
treat
vaccin
term
bacteri
exacerb
anoth
studi
show
patient
treat
pidotimod
plu
amoxicillin
clavulan
acid
faster
remiss
symptom
compar
treat
antibiot
moreov
pidotimod
seen
abl
increas
product
secretori
iga
patient
copd
contribut
defin
pidotimod
potenti
strategi
prevent
infect
asthma
phenotyp
endotyp
base
inflammatori
airway
involv
nowaday
increas
medic
interest
thank
develop
target
therapi
aim
hamper
directli
mechan
underli
patholog
process
least
two
big
group
endotyp
far
identifi
endotyp
character
cytokin
overexpress
particularli
concomit
airway
eosinophil
inflamm
inflammatori
endotyp
neutrophil
predomin
inflammatori
cell
within
airway
endotyp
asthma
distinguish
allerg
non
allerg
eosinophil
asthma
former
result
allerg
reaction
typic
childhood
onset
latter
result
eosinophil
inflamm
toward
unknown
trigger
typic
adult
onset
often
associ
chronic
rhinosinus
nasal
polyposi
aspirin
hypersensit
mention
endotyp
present
wide
rang
sever
asthmat
classifi
affect
sever
asthma
requir
high
dose
inhal
corticosterpoid
ic
plu
second
control
andor
system
glucocorticoid
prevent
asthma
becom
uncontrol
remain
uncontrol
despit
therapi
one
peculiar
featur
sever
asthma
high
frequenc
exacerb
often
associ
respiratori
tract
infect
account
major
fraction
total
heathcar
relat
cost
asthma
moreov
person
approach
asthma
prescind
diagnosi
treatment
comorbid
particular
rhiniti
chronic
rhinosinus
crswnp
without
nasal
polyp
crssnp
recent
crosssect
studi
show
crsrelat
exacerb
associ
lost
product
asthmat
assess
number
lost
day
work
school
anoth
common
comorbid
sever
asthma
bronchiectasi
estim
present
patient
bronchiectasi
irrevers
enlarg
airway
bring
predisposit
develop
recurr
often
sever
lower
respiratori
tract
infect
trigger
asthma
exacerb
complex
context
patient
asthma
particularli
sever
clearli
prone
develop
exacerb
link
upper
lower
airway
infect
immunostimulatori
approach
pidotimod
may
benefici
preclin
evid
alreadi
avail
studi
investig
abil
pidotimod
affect
vitro
phenotyp
cytokin
profil
blood
cell
relat
atop
asthma
show
abl
downregul
express
mononuclear
cell
isol
atop
asthmat
children
healthi
control
associ
cell
observ
support
possibl
pidotimod
abl
affect
balanc
atop
asthma
asthma
endotyp
patient
tend
react
target
therapi
patholog
type
inflamm
glucocorticosteroid
recent
studi
support
theori
nk
cell
cytotox
function
disabl
part
steroid
sever
asthma
nk
cell
express
special
proresolv
mediat
spm
pivot
signal
resolut
tissu
inflamm
nevertheless
spm
abund
signal
receptor
disrupt
chronic
inflammatori
diseas
spm
receptor
spm
instanc
counter
deleteri
effect
corticosteroid
effector
function
nk
cell
togeth
find
suggest
sever
asthma
patient
alreadi
refractori
benefici
action
corticosteroid
may
harm
steroid
increas
suscept
viral
infect
asthma
exacerb
thu
leav
unveil
indic
use
pidotimod
patient
act
prevent
viral
infect
asthma
exacerb
europ
approxim
popul
affect
allerg
rhiniti
ar
frequent
accompani
allerg
asthma
aa
preval
increas
less
individu
without
ar
ar
combin
upper
lower
respiratori
symptom
increas
overal
impact
patient
consider
evid
symptom
ar
aa
neg
affect
patient
health
relat
qualiti
life
allergen
immunotherapi
ait
nowaday
treatment
specif
target
allerg
inflammatori
pathway
repres
prototyp
person
medicin
approach
respiratori
diseas
patient
ait
highli
effect
may
induc
longterm
remiss
symptom
howev
ongo
problem
includ
durat
treatment
safeti
immunotherapi
cost
access
adjuv
potenti
modifi
pharmacolog
immunolog
effect
allergen
vaccin
may
modul
allergen
deliveri
act
depot
stimul
immun
respons
limit
antibodi
respons
order
reduc
unwant
side
effect
adjuv
may
use
combin
potenti
cumul
effect
therefor
sinc
pidotimod
action
pathway
includ
effect
tslp
action
fig
could
open
interest
unexplor
option
adjuv
treatment
allergen
immunotherapi
depend
choos
rout
administr
recent
studi
use
pidotimod
chicken
vaccin
newcastl
diseas
viru
vaccin
reveal
pidotimod
could
significantli
promot
growth
perform
lymphocyt
prolifer
enhanc
serum
antibodi
titer
cell
ratio
improv
serum
concentr
indic
significantli
improv
immun
efficaci
newcastl
diseas
vaccin
reinforc
role
immunostimul
alreadi
well
establish
previou
literatur
find
last
year
sever
immunostimul
natur
synthet
origin
work
differ
mechan
creat
prevent
rrti
clinic
experi
show
good
evid
role
immunostimul
adjuv
treatment
respiratori
diseas
children
far
less
exist
adult
among
current
avail
immunostimul
pidotimod
potenti
characterist
one
effect
adjuv
strategi
respiratori
diseas
highqual
largescal
random
control
studi
reallif
experi
essenti
provid
confirmatori
evid
